This modeling study uses 3 microsimulation models of a hypothetical cohort to model the benefits, burden, and harms of colorectal cancer screening strategies to inform the 2016 update of US Preventive Services Task Force Recommendation Statement.
This Recommendation Statement from the US Preventive Services Task Force recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation) and recommends that for adults aged 76 to 85 years the decision to screen for colorectal cancer should be an individual one that takes into account the patient’s overall health and prior screening history (C recommendation).
This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on screening for colorectal cancer summarizes published evidence about the effectiveness of routine screening, accuracy of screening tests and strategies, and potential screening harms.
This Viewpoint discusses the basis for the FDA’s 2016 approval of the blood-based septin 9 gene (SEPT9) assay as a screening test for colon cancer and concerns about its accuracy and use in clinical practice.
This Viewpoint discusses the need to account for clinician and patient adherence to colorectal cancer screening recommendations and barriers to implementation of screening programs in the choice of which tests to recommend in screening guidelines
This simulation study uses Kaiser Permanente patient data to estimate benefits, complications, and costs of colorectal cancer screening stratified by adenoma detection rate and age at initiation.
The FDA has approved a stool DNA test to screen average-risk adults ≥50 years old for colorectal cancer.